Recent months have brought the lab into conversations across transplantation, autoimmunity, cancer immunology, and type 1 diabetes. The disease areas are different, but many of the questions keep coming back to the same place: which antigens matter, which T cells recognize them, and how can we build better tools to study those responses directly in human disease?

Mo was invited to present the lab’s antigen-discovery work at several forums, including the NIH/NIAID Clinical Trials in Organ Transplantation (CTOT) Workshop in Washington, DC; the Translational Research Cancer Centers Consortium (TRCCC) Annual Meeting in Seven Springs, Pennsylvania; the Sjögren’s Foundation National Patient Conference; the Arthritis National Research Foundation (ANRF) Webinar Series; the American Diabetes Association (ADA) Scientific Sessions in New Orleans; and programs hosted by the Colton Center for Autoimmunity at Penn. These meetings have also been a valuable opportunity to learn from different communities and better understand how related questions are being approached across fields.

Together, these talks highlighted the lab’s broader effort to develop genome-scale platforms for T cell antigen discovery and apply them to major questions in human disease. The lab also received support from the Penn Diabetes Research Center Pilot and Feasibility Program to help advance antigen-discovery technologies for type 1 diabetes and deepen our understanding of the underlying mechanisms of disease.